Aloe Therapeutics is pioneering a novel approach to cancer treatment through its Allo-Immunotherapy (AIM) platform, which functions as a locally delivered immunotherapy designed to enhance the immune response against tumors. AIM acts as an in situ vaccine, directly implanted at the tumor site to stimulate an influx of immune cells into the tumor microenvironment. This technology aims to convert "cold" tumors, which are typically resistant to immune responses, into "hot" tumors that are more susceptible to treatment. By doing so, AIM seeks to improve the efficacy of existing checkpoint immunotherapy and expand treatment options for patients with limited alternatives.

The AIM platform is characterized by its allogeneic, "off-the-shelf" nature, which eliminates the need for complex and costly cell engineering. It is designed to remain at the tumor site during procedures such as biopsy or tumor resection, effectively serving as a bait for the immune system. This localized delivery not only enhances anti-tumor activity but also allows for easy integration into current treatment regimens, including surgery, chemotherapy, and other immunotherapies. The technology is versatile, with applications across various solid tumor types, including challenging cases like unresectable tumors and pediatric indications, while minimizing systemic toxicity and allowing for re-dosing to boost immune response.

United States

Aloe Therapeutics is a biotech start-up aimed at delivering cancer cures. We have designed a therapy, termed Allo-Immunotherapy (AIM), to trigger an influx of activated immune cells to traffic to the tumor microenvironment - turning "cold" tumors "hot" and "hot" tumors "hotter." INFLAME WITH AIM.

Aloe Therapeutics

Company Details